Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Gains from Investment Securities (2016 - 2025)

Sutro Biopharma's Gains from Investment Securities history spans 9 years, with the latest figure at -$157000.0 for Q3 2025.

  • For Q3 2025, Gains from Investment Securities fell 101.01% year-over-year to -$157000.0; the TTM value through Sep 2025 reached $574000.0, down 96.34%, while the annual FY2024 figure was $8.7 million, 9.7% up from the prior year.
  • Gains from Investment Securities for Q3 2025 was -$157000.0 at Sutro Biopharma, down from $62739.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $15.6 million in Q3 2024 and bottomed at -$14.7 million in Q4 2024.
  • The 5-year median for Gains from Investment Securities is $18366.0 (2021), against an average of $35958.3.
  • The largest YoY upside for Gains from Investment Securities was 5163.64% in 2024 against a maximum downside of 6946.63% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at -$884000.0 in 2021, then surged by 168.67% to $607000.0 in 2022, then tumbled by 134.27% to -$208000.0 in 2023, then plummeted by 6946.63% to -$14.7 million in 2024, then surged by 98.93% to -$157000.0 in 2025.
  • Per Business Quant, the three most recent readings for STRO's Gains from Investment Securities are -$157000.0 (Q3 2025), $62739.0 (Q2 2025), and $117523.0 (Q1 2025).